Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

Inclusion criteria

• Confirmed histologic diagnosis of invasive adenocarcinoma of the breast
• ER, PR and HER2 testing, and
• TNBC patients （ HER2-neu 0-1+ by IHC or FISH-negative by ASCO CAP guidelines）
• ER-positive and HER2-negative breast cancer
• tumor measuring ≥2 cm in maximal diameter as measured by any available standard of care imaging (mammogram, breast ultrasound, breast MRI)
• Any nodal status
• ECOG Performance Status of 0 -1
• Screening laboratory values must meet the following criteria:

i. Absolute neutrophil count (ANC) ≥1.5 × 109/L ii. Platelets ≥100 × 109/L iii. Hemoglobin ≥ 10.0 g/dl for TNBC, ≥ 10.0 g/dl for HR+/HER2-BC iv. Serum creatinine ≤1.5 x upper limit of normal (ULN) v. AST ≤ 2.5 xULN vi. ALT ≤ 2.5 x ULN vii. Total bilirubin ≤ 2.5 xULN viii left ventricular ejection fraction ≥ 50%.

Exclusion criteria

• Any kind of prior treatment for breast cancer, including chemotherapy, radiotherapy, endocrine therapy and so on
• Inflammatory breast cancer
• Pregnant and lactating women;
• distant metastasis
• patients who have participated in other clinical trials.